About Sunways
Sunways is a Healthcare company based in Mumbai (India) founded in 1951. It operates as an ophthalmic and ENT products are manufactured, along with medical devices. Sunways has raised $15 million across 1 funding round from investors including InvAscent. Sunways has completed 2 acquisitions, including Inor Medical Products and Inor Orthopaedics. Sunways was last valued at $41.86 million in October 2022. Its Indian entity Sunways (India) Private Limited reported revenue of ₹143 Cr. Sunways offers products and services including Ophthal Products, ENT Products, and Medical Devices. Its focus areas include Diversified Pharmaceuticals and Drugs. Its competitors include Annexon, Aldeyra, Lyra Therapeutics, Nicox and Decibel Therapeutics and 5 more; 8 of its 10 listed competitors have raised funding.
Company details
Sunways was founded in 1951 and is based in Mumbai, India. Ophthalmic and ENT products are manufactured, alongside medical devices. Eye drops and ointments are supplied to support healthcare applications. Medical education programs are backed by the company. Operations emphasize expansion into additional therapeutic areas to meet evolving healthcare requirements in the sector.
- Headquarters Mumbai, India
- Stage Minicorn
- SectorsHealthcare
- Website category Health · Pharmacy
- Email••••••••
- Phone•••• ••••
- Website sunways.com
- Social LinkedIn
- Legal Name Sunways India Pvt Ltd
- Date of Incorporation 27 Jul, 1990
- Jurisdiction Mumbai, Maharashtra, India
- Annual Revenue₹143 Cr
FY 2024 · +10% YoY
- Net Profit₹31.10 Cr
FY 2024 · 22% margin
- EBITDA₹46.20 Cr
FY 2024 · 32% margin
- Total Equity Funding$15M (USD)
in 1 rounds
- Latest Funding Round$15M (USD), Series B
Oct 2022
- Investors
- Investments & AcquisitionsInor Medical Products
& 1 more
Associated legal entities of Sunways
Sunways is associated with 3 registered companies on The Company Check; the primary company is Sunways (India) Private Limited. Each company page carries the filings, financials, charges and directors of that entity.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2024) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Sunways (India) Private Limited CIN U85195MH1990PTC057447 | Active | 27 Jul 1990 | Mumbai, Maharashtra | ₹143 Cr | 564 | 6 | View details |
| Sunways Rohto Pharmaceutical Private Limited CIN U24231GJ1986PTC008689 | Active | 22 May 1986 | Ahmedabad, Gujarat | ₹16.1 Cr | 87 | 5 | View details |
| Raf Holdings Private Limited CIN U70100MH1953PTC009097 | Active | 22 Jul 1953 | Maharashtra, India | ₹3.3 Cr | 123 | 3 | View details |
Products & Services of Sunways
Sunways offers a comprehensive portfolio of products and services, including Ophthal Products, ENT Products, and Medical Devices.
Products for eye treatment and care, including drops and ointments
Items for ENT care and treatment
Devices supporting medical applications in eyecare and ENT
Funding Insights of Sunways
Sunways has successfully raised a total of $15M through 1 strategic funding round. The most recent funding activity was a Series B round of $15 million completed in October 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $15M
- Total Rounds 1
- Last Round Series B — $15M
- First Round $15M
(Oct 2022)
- Investors Count 1
All 1 funding rounds of Sunways with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2022 | $15M | Series B | $41.86M | InvAscent | – |
| Date | Valuation | Stage |
|---|---|---|
| Oct 2022 | $41.86M | •••••••• |
Last known valuation $41.86M (Oct 2022). 1 investors in total: 1 institutional.
Investors in Sunways
Sunways has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include InvAscent.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity firm focused on life sciences investments in India. | 2005 | invascent.com | - |
Investor details for Sunways
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Sunways (India) Private Limited (Sunways)
Sunways (India) Private Limited is the primary company behind Sunways. The boards of the 3 registered companies of Sunways currently have 8 directors; the longest-serving is Bhadresh Kantilal Shroff, appointed in 1992. 18 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Bhadresh Kantilal Shroff DIN 02027248 | Managing Director | 20 Mar 1992 | 34 yrs 7 mo | Sunways Rohto Pharmaceutical Private Limited, Raf Holdings Private Limited, Sunways (India) Private Limited |
| Anupam Kantilal Shroff DIN 02027234 | Director | 16 Oct 2017 | 9 yrs | Sunways Rohto Pharmaceutical Private Limited, Raf Holdings Private Limited, Sunways (India) Private Limited |
| Firaq Pankaj Shroff DIN 02027528 | Director | 23 Apr 2019 | 7 yrs 5 mo | Raf Holdings Private Limited, Sunways (India) Private Limited |
| Daiki Kato DIN 08816915 | Additional Director | 15 Jul 2020 | 6 yrs 3 mo | Sunways Rohto Pharmaceutical Private Limited |
| Aatish Anupam Shroff DIN 07557575 | Director | 21 Oct 2022 | 4 yrs | Sunways (India) Private Limited |
| Ratheen Bhadresh Shroff DIN 07557577 | Director | 21 Oct 2022 | 4 yrs | Sunways (India) Private Limited |
| Sumit Gupta DIN 06401402 | Additional Director | 16 Mar 2023 | 3 yrs 7 mo | Sunways Rohto Pharmaceutical Private Limited |
| Anil Kumar Jagirdar DIN 09188416 | Nominee Director | 30 Sep 2024 | 2 yrs | Sunways Rohto Pharmaceutical Private Limited, Sunways (India) Private Limited |
People of Sunways
4 people are tracked at Sunways (4 in leadership).
| Name | Role | Group |
|---|---|---|
| Owner | Leadership | |
| Managing Director | Leadership | |
| Exec. Director - Business Operations | Leadership | |
Finance Ratheen Shroff Msc (IT) | Director Of Business Development / International Operations | Leadership |
Complete people profiles for Sunways
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Sunways
Figures of Sunways (India) Private Limited, the primary company behind Sunways, for FY 2024. Revenue was ₹143 Cr (+10% year on year). Net profit was ₹31.10 Cr (22% margin). EBITDA was ₹46.20 Cr (32% margin). Revenue has grown at a compounded annual rate of +22% over three years and +34% over five years.
- ₹143 CrRevenue · FY 2024 · +10% YoY
- ₹31.10 CrNet profit · 22% margin
- ₹46.20 CrEBITDA · 32% margin
- ₹6.9 LakhPaid-up capital
- 564Employees (provident fund records)
- +22%Revenue CAGR, 3 years
- +34%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Sunways (India) Private Limited are on its company page.
Detailed financial statements for Sunways
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Sunways
Sunways has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Inor Medical Products and Inor Orthopaedics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Orthopedic products and ophthalmic instruments are manufactured. | inormedical.com | Mumbai, India | 2021 | Feb 2021 | •••• | |
Orthopedic devices are manufactured by Inor Orthopaedics in India. | inorortho.com | Mumbai, India | 2009 | Feb 2021 | •••• |
Complete acquisition details for Sunways
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Sunways
5 dated milestones of Sunways across 71 years, from founding to its latest funding, stage changes and deals.
- Founded Sunways is founded.
- Acquisition Acquires Inor Orthopaedics.
- Acquisition Acquires Inor Medical Products.
- Funding First funding round of $15.0M.
- Milestone Reaches Minicorn status.
Competitors of Sunways
Sunways has 10 listed competitors in our database, 8 of them funded. They include Annexon, Aldeyra, Lyra Therapeutics, Nicox and Decibel Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| annexonbio.com | 2011 | San Francisco, United States | $256M | 80 | Developer of antibodies to treat complement-mediated neurodegenerative diseases | |
| aldeyra.com | 2004 | Lexington, United States | $4.79M | 30 | Drug candidates for immune-mediated diseases are developed by Aldeyra. | |
| lyratherapeutics.com | 2005 | Watertown, United States | $127.61M | 75 | Small molecule therapeutics for ENT diseases are developed. | |
| nicox.com | 1996 | Valbonne, France | $271.01M | – | Nitric oxide-based therapeutics for glaucoma and eye conditions are developed. | |
| decibeltx.com | 2015 | Cambridge, United States | $169.53M | 62 | Medicines are developed to protect, repair, and restore hearing capacity. | |
| gyroscope.cc | 2016 | San Francisco, United States | – | – | Mobile SDK developed for app engagement and monetization strategies. | |
| meiragtx.com | 2015 | New York, United States | – | 358 | Gene therapies for ocular and neurodegenerative diseases are developed. | |
| gensight-biologics.com | 2011 | Paris, France | $76.63M | – | Viral vector-based gene therapies for retinal diseases are developed. | |
| kriyatherapeutics.com | 2012 | Redwood, United States | $930.93M | 159 | Developer of therapeutic solutions for the treatment of diabetes | |
| alimerasciences.com | 2003 | Alpharetta, United States | $66.8M | 79 | Ophthalmic pharmaceuticals for diabetic macular edema are developed and commercialized. |
Detailed competitors of Sunways
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Sunways
The website of Sunways (sunways.com) receives about 4.8K visits a month and ranks #3,644,677 among all websites worldwide, #4,039 in Pharmacy.
- Monthly visits4.8K
▲ 19.4% vs previous month
- Unique visitors1.7K
per month
- Global rank#3,644,677
among all websites
- Category rank#4,039
Health · Pharmacy
- Bounce rate26%
- Pages per visit2.9
- Average visit1 min 18 sec
- DevicesDesktop 50% · Mobile 50%
Websites whose visitors overlap most with Sunways. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| hplbd.com | 100% | – | #960,982 | View details | |
isee.com | isee.com | 54% | – | – | – |
| eyecarespecialties.com | 54% | 4.1K | #4,778,193 | View details | |
sunways-tech.com | sunways-tech.com | 34% | – | #1,779,205 | – |
Top companies in Pharmaceuticals & Distribution
10 companies that operate in the same segment as Sunways (Pharmaceuticals & Distribution), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Pharmaceutical products are manufactured and marketed worldwide. | 1891 | Kenilworth, Warwickshire, United Kingdom | – | USD 64.93 B | 781 | |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | – | USD 33.23 B | 28,000 | |
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | – | USD 61.16 B | 55,000 | |
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | United States | – | USD 65.18 B | 47,000 | |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | 1987 | Foster City, California, United States | – | USD 29.45 B | 17,600 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 213.52 M | USD 29.62 M | 225 | |
Developer of medical devices, generic pharmaceuticals, and nutrition products | 1888 | Libertyville, Illinois, United States | – | USD 44.33 B | 3,710 | |
Medicines and health products are retailed through pharmacy outlets. | 2006 | Hyderabad, Telangana, India | USD 268.78 M | USD 734.57 M | 25,010 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Sunways
Complete news archive for Sunways
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sunways
Sunways was founded in 1951 and raised its 1st funding round 71 years after it was founded.
Sunways is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.
Sunways is a funded company, having raised a total of $15M across 1 funding round to date. The company's 1st funding round was a Series B of $15M, raised on Oct 2022.
The primary company behind Sunways, Sunways (India) Private Limited, reported revenue of ₹143 Cr for FY 2024, up 10% year on year.
Sunways was founded in 1951 and is based in Mumbai, India. Ophthalmic and ENT products are manufactured, alongside medical devices. Eye drops and ointments are supplied to support healthcare applications. Medical education programs are backed by the company. Operations emphasize expansion into additional therapeutic areas to meet evolving healthcare requirements in the sector.
Sunways's top competitors include Annexon, Decibel Therapeutics and Alimera Sciences.
Sunways offers Ophthal Products, ENT Products, and Medical Devices.
Sunways has made 2 acquisitions, including Inor Medical Products, and Inor Orthopaedics.
Sunways has 1 investor. Key investors include InvAscent.
The valuation of Sunways is $41.86M as of Oct 2022.
Sunways is associated with 3 legal entities: Sunways (India) Private Limited, Sunways Rohto Pharmaceutical Private Limited, Raf Holdings Private Limited.
The legal entities of Sunways currently have 8 directors, including Sumit Gupta, Anil Kumar Jagirdar, Daiki Kato and others.